Quest Diagnostics (DGX) SVP awarded 5,682 shares; 2,326 withheld for taxes

Rhea-AI Filing Summary

Quest Diagnostics senior executive Mark E. Delaney reported stock-based compensation activity involving company common stock. On March 4, 2026, he acquired 5,682 shares of Quest Diagnostics common stock at a value of $204.86 per share through the settlement of a performance stock award approved under Rule 16b-3(d).

On the same date, 2,326 shares of common stock were disposed of back to Quest Diagnostics solely to cover tax withholding obligations related to that award, as indicated in the footnotes. Following these transactions, Delaney directly owned 11,864 shares of Quest Diagnostics common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider DELANEY MARK E

Role SVP & Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,682	$204.86	$1.16M
Tax Withholding	Common Stock	2,326	$204.86	$477K

Holdings After Transaction: Common Stock — 14,190 shares (Direct)

Footnotes (1)

1. Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d). Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DELANEY MARK E

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		5,682(1)	A	$204.86	14,190	D
Common Stock	03/04/2026		F		2,326(2)	D	$204.86	11,864	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d).

2. Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award.

Remarks:

	Sean D. Mersten, Attorney in Fact for Mark E. Delaney	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Quest Diagnostics (DGX) report for Mark E. Delaney?

Quest Diagnostics reported that Mark E. Delaney received a grant of 5,682 shares of common stock on March 4, 2026, from a settled performance stock award, and 2,326 shares were simultaneously withheld to satisfy related tax obligations.

Was the Quest Diagnostics (DGX) Form 4 transaction an open-market stock purchase or sale?

The Form 4 shows no open-market buy or sell. Shares were acquired through a performance stock award settlement and disposed of back to Quest Diagnostics only to cover tax withholding obligations, according to the filing footnotes.

How many Quest Diagnostics (DGX) shares does Mark E. Delaney own after this Form 4?

After the reported transactions, Mark E. Delaney directly owns 11,864 shares of Quest Diagnostics common stock. This reflects the net position following the award of 5,682 shares and the tax-withholding disposition of 2,326 shares to the company.

What does the acquisition of 5,682 Quest Diagnostics (DGX) shares represent for Mark E. Delaney?

The 5,682 shares represent stock issued in settlement of a performance stock award approved under Rule 16b-3(d). This indicates compensation tied to performance rather than a cash purchase in the open market by the executive.

Why were 2,326 Quest Diagnostics (DGX) shares disposed of in Mark E. Delaney’s Form 4?

The filing states that 2,326 shares of Quest Diagnostics common stock were returned to the issuer solely to cover tax withholding obligations arising from the settlement of the performance stock award granted to Mark E. Delaney.

At what price were Mark E. Delaney’s Quest Diagnostics (DGX) Form 4 transactions valued?

Both the acquisition and tax-withholding disposition transactions in the Form 4 are valued at $204.86 per share. This per-share value is used for the 5,682 shares issued and the 2,326 shares withheld for taxes.